[關鍵詞]
[摘要]
目的 分析鑒定大鼠ig太子參環(huán)肽提取物后血漿、膽汁、尿液及糞便的代謝產(chǎn)物,并推測其在大鼠體內(nèi)的代謝途徑。方法 雄性SD大鼠ig太子參環(huán)肽類提取物(400 mg·kg-1),給藥后收集血漿、膽汁、尿液及糞便樣品。樣品處理后,采用超高效液相色譜-四極桿-靜電場軌道離子阱質(zhì)譜技術(UPLC-Q-Exactive MS)分析環(huán)肽的入血原型成分,對其中2種入血環(huán)肽heterophyllin (HA)、pseudostellaria C(PC)代謝物進行結構表征。結果 共從大鼠血漿中提取到了7種環(huán)肽類成分,包括pseudostellarin A、pseudostellarin B、heterophyllin B、PC、pseudostellarin D、HA、pseudostellarin E;在大鼠的生物樣本中檢測到13個HA代謝產(chǎn)物,其中血漿、膽汁、尿液、糞便分別鑒定出3、7、0、13個;PC代謝產(chǎn)物有15個,其中血漿、膽汁、尿液、糞便分別有3、10、4、14個。2種環(huán)肽在大鼠體內(nèi)存在去羥基化、水解、脫水、甲基化代謝途徑。結論 通過UPLCQ-Exactive MS技術推測出了HA和PC代謝產(chǎn)物和途徑。
[Key word]
[Abstract]
Objective To analyze and identify the metabolites present in plasma, bile, urine and feces after gavage of the cyclic peptide extract of Pseudostellaria heterophylla and to speculate on the metabolic pathways of different structural cyclic peptides in rats. Methods Male SD rats were ig administered cyclic peptide extract (400 mg·kg-1), and plasma, bile, urine and feces samples were collected. After the samples were processed, the metabolites of two of the blood entry cyclic peptides, heterophyllin A (HA) and pseudostellaria C (PC) were structurally characterized by ultra-high-performance liquid chromatography-quadrupoleelectrostatic field orbital ion trap mass spectrometry (UPLC-Q-Exactive MS). Results Seven cyclic peptide components were extracted from plasma, including pseudostellarin A, pseudostellarin B, heterophyllin B, PC, pseudostellarin D, HA, and pseudostellarin E. 13 metabolites of HA and 15 metabolites of PC were detected in biological samples from rats. 3, 7, 0, and 13 of HA metabolites and 3, 10, 4, and 14 of PC metabolites were identified in plasma, bile, urine, and feces, respectively, and the metabolism of the two cyclic peptides in rats was elucidated through the pathways of dehydroxylation, hydrolysis, dehydration, and methylation. Conclusion The metabolites of HA and PC were deduced by UPLC-Q-Exactive MS.
[中圖分類號]
R917
[基金項目]
福建省省屬公益類科研院所科研專項項目(2021R1003006);福建省自然科學基金項目(2021J01913,2020J01723);國家重點研發(fā)計劃“中醫(yī)藥現(xiàn)代化研究”重點專項(2019YFC1710504)